-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29

Benzinga·10/28/2026 12:45:05
Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $32 to $29.